Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera [4]

British Journal of Haematology

Volumn 139, Issue 3, 2007, Pages 511-512

  Scott, Linda M ^a   Beer, Philip A ^a   Bench, Anthony J ^a   Erber, Wendy N ^a   Green, Anthony R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Mutations; Myeloproliferative disorder; Polycythaemia vera

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; STAT5A PROTEIN; STAT5B PROTEIN;

ALLELE; ERYTHROCYTOSIS; EXON; GENE IDENTIFICATION; HUMAN; IDIOPATHIC DISEASE; LETTER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

AGED, 80 AND OVER; BASE SEQUENCE; FEMALE; HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA;

EID: 34848910714     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06806.x     Document Type: Letter

References (8)

1. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C.L., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N., Green, A.R. the Cancer Genome Project 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
2. Campbell, P.J. Green, A.R. (2006) The myeloproliferative disorders. New England Journal of Medicine, 355, 2452 2466.
3. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. Green, A.R. (2005) Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945 1953.
4. Pardanani, A., Lasho, T.L., Finke, C., Hanson, C.A. Tefferi, A. (2007) Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21, 1960 1963.
5. Pearson, T.C. (2001) Evaluation of diagnostic criteria in polycythemia vera. Seminars in Hematology, 38 (Suppl. 2 21 24.
6. Percy, M.J., Scott, L.M., Erber, W.N., Harrison, C.N., Reilly, J.T., Jones, F.G.C., Green, A.R. McMullin, M.F. (2007) JAK2 exon 12 mutations occur frequently in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica, in press.
7. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459 468.
8. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092 1097.